• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.280 -0.030 (-0.91%)
Official Closing Price Updated: 4:15 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
News headline image
Recursion to Participate in Upcoming Investor Conferences
April 07, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
March 31, 2026
From Citeline
Via GlobeNewswire
News headline image
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
March 25, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Stocks Under $5 to Watch Now: LRMR, RXRX, NDRA, BTQ, CDIO Watch Now!
February 26, 2026
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
July 29, 2025
Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
July 08, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
February 23, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
February 23, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
February 18, 2026
Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
February 12, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Myseum (NASDAQ: MYSE) Ignites “Picture Party,” a New Era in Social Media on All Apple (NASDAQ: AAPL) Devices Now! more stocks inside…
December 17, 2025
Via AB Newswire
Topics Artificial Intelligence
News headline image
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
December 08, 2025
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
December 01, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
November 05, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
November 05, 2025
Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
November 04, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
October 28, 2025
Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
August 27, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
August 12, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
August 05, 2025
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Doctors Are Being Outpaced by AI-Powered Algorithms — Here’s What It Means for Investors
July 07, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:MSFT),(NASDAQ:ASTH),(NASDAQ:RXRX),(NASDAQ:MDAI) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Fraud
News headline image
Capital Flows Shift From Research Labs to Pharmacy Counters-A Watershed Moment for AI Health
June 17, 2025
Issued on behalf of Avant Technologies Inc. Vancouver, BC – June 17, 2025 – USA News Commentary – Momentum continues to build behind AI in healthcare, as capital finds its way to technologies capable... 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
June 06, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
May 30, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
May 06, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
May 05, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap